Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of BGM0504 injection in Chinese patients with poorly controlled type 2 diabetes mellitus
CTR20244494Phase 3Active
- Sponsor
- Borray New Creation Biopharmaceutical Technology
- Start
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of BGM0504 in type 2 diabetes mellitus (T2DM), sponsored by Borray New Creation Biopharmaceutical Technology. Started Jan 2025; status: active.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244494.